Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates
Portfolio Pulse from
Heron Therapeutics reported a Q4 2024 GAAP net income of $3.6 million and a full-year 2024 net revenue of $144.2 million, marking a 14% increase year-over-year. The company also launched the ZYNRELEF Vial Access Needle and won a patent lawsuit against Fresenius Kabi USA.
February 27, 2025 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heron Therapeutics achieved a Q4 2024 net income of $3.6 million and a 14% increase in full-year revenue. The launch of ZYNRELEF VAN and a favorable patent ruling are positive developments.
The financial results show strong performance with increased revenue and net income, which is positive for stock prices. The launch of a new product and a favorable legal ruling further enhance the company's market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100